Who are Levetiracetam (Keppra)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Antiepileptic drug (AED), Levetiracetam (LEV), Lacosamide - conventional titration, Keppra® extended release formulation - XR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levetiracetam-keppra.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Levetiracetam (Keppra) — Competitive Intelligence Brief

Levetiracetam (Keppra) (Levetiracetam (Keppra)) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiepileptic drug (AED). Area: Neurology.

marketed Antiepileptic drug (AED) SV2A (synaptic vesicle protein 2A) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Levetiracetam (Keppra) (Levetiracetam (Keppra)) — UCB Pharma. Levetiracetam reduces seizure activity by binding to synaptic vesicle protein SV2A and modulating neurotransmitter release.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Levetiracetam (Keppra) TARGET	Levetiracetam (Keppra)	UCB Pharma	marketed	Antiepileptic drug (AED)	SV2A (synaptic vesicle protein 2A)
Antiepileptic drug (AED)	Antiepileptic drug (AED)	Oslo University Hospital	marketed	Antiepileptic drug (AED)
Levetiracetam (LEV)	Levetiracetam (LEV)	UCB Japan Co. Ltd.	marketed	Antiepileptic drug (AED)	SV2A (synaptic vesicle protein 2A)
Lacosamide - conventional titration	Lacosamide - conventional titration	Seoul National University Hospital	marketed	Antiepileptic drug (AED)	Voltage-gated sodium channels (slow inactivation enhancer)
Keppra® extended release formulation - XR	Keppra® extended release formulation - XR	UCB Pharma	phase 3	Antiepileptic drug (AED)	SV2A (synaptic vesicle protein 2A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiepileptic drug (AED) class)

UCB Pharma · 2 drugs in this class
Oslo University Hospital · 1 drug in this class
Seoul National University Hospital · 1 drug in this class
UCB Japan Co. Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levetiracetam (Keppra) — Competitive Intelligence Brief. https://druglandscape.com/ci/levetiracetam-keppra. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab